ArticlePloS one2021
Body mass index and severity/fatality from coronavirus disease 2019: A nationwide epidemiological study in Korea.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis.International journal of cancer · 2024Pooled it
- Obesity as a Risk Factor for Complications and Mortality in Individuals with SARS-CoV-2: A Systematic Review.Nutrients · 2024Pooled it
- Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis.Diabetologia · 2023Pooled it
- Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression.Frontiers in endocrinology · 2022Pooled it
- Magnitude, associated risk factor and awareness of predisposing factors, treatment, and prevention of overweight/obesity among adults in North Wollo zone, Northeast Ethiopia.Frontiers in nutrition · 2025Article
- Obesity Parameters as Predictor of Poor Outcomes in Hospitalized Patients with Confirmed Mild-to-Moderate COVID-19.Infectious disease reports · 2024Article
- Correction: Body mass index and severity/fatality from coronavirus disease 2019: A nationwide epidemiological study in Korea.PloS one · 2024Article
- Comparison between Neutralization Capacity of Antibodies Elicited by COVID-19 Natural Infection and Vaccination in Indonesia: A Prospective Cohort.Antibodies (Basel, Switzerland) · 2023Article
- Hen egg white bovine colostrum supplement reduces symptoms of mild/moderate COVID-19: a randomized control trial.Future science OA · 2023Article
- SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients.Frontiers in immunology · 2023Article
- Mediating factors explain anxiety experienced by women with obesity during the Covid-19 pandemic.PloS one · 2023Article
- Association of BMI with general health, working capacity recovered, and post-acute sequelae of COVID-19.Obesity (Silver Spring, Md.) · 2023Article
- The obesity paradox in Japanese COVID-19 patients.International journal of medical sciences · 2023Article
- Vitamin C as a Potential Interplaying Factor between Obesity and COVID-19 Outcome.Healthcare (Basel, Switzerland) · 2022Article
- A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV.Vaccines · 2022Article
- Role of body mass index in outcomes of patients hospitalized with COVID-19 illness.Obesity science & practice · 2022Article
- The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-19.Best practice & research. Clinical haematology · 2022Article
- Differences in mortality rate among patients hospitalized with severe COVID-19 according to their body mass index.Obesity science & practice · 2022Article
- Impact of body mass index on the outcome of Japanese patients with cardiovascular diseases and/or risk factors hospitalized with COVID-19 infection.Journal of cardiology · 2022Article
- Obesity and Its Impact on Adverse In-Hospital Outcomes in Hospitalized Patients With COVID-19.Frontiers in endocrinology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveObesity has been reported as a risk factor for severe coronavirus disease 2019 (COVID-19) in recent studies. However, the relationship between body mass index (BMI) and COVID-19 severity and fatality are unclear. RESEARCH DESIGN AND
methodsThis study included 4,141 COVID-19 patients who were released from isolation or had died as of April 30, 2020. This nationwide data was provided by the Korean Centers for Disease Control and Prevention Agency. BMI was categorized as follows; < 18.5 kg/m2, 18.5-22.9 kg/m2, 23.0-24.9 kg/m2, 25.0-29.9 kg/m2, and ≥ 30 kg/m2. We defined a fatal illness if the patient had died.
resultsAmong participants, those with a BMI of 18.5-22.9 kg/m2 were the most common (42.0%), followed by 25.0-29.9 kg/m2 (24.4%), 23.0-24.9 kg/m2 (24.3%), ≥ 30 kg/m2 (4.7%), and < 18.5 kg/m2 (4.6%). In addition, 1,654 (41.2%) were men and 3.04% were fatalities. Multivariable analysis showed that age, male sex, BMI < 18.5 kg/m2, BMI ≥ 25 kg/m2, diabetes mellitus, chronic kidney disease, cancer, and dementia were independent risk factors for fatal illness. In particular, BMI < 18.5 kg/m2 (odds ratio [OR] 3.97, 95% CI 1.77-8.92), 25.0-29.9 kg/m2 (2.43, 1.32-4.47), and ≥ 30 kg/m2 (4.32, 1.37-13.61) were found to have higher ORs than the BMI of 23.0-24.9 kg/m2 (reference). There was no significant difference between those with a BMI of 18.5-22.9 kg/m2 (1.59, 0.88-2.89) and 23.0-24.9 kg/m2.
conclusionsThis study demonstrated a non-linear (U-shaped) relationship between BMI and fatal illness. Subjects with a BMI of < 18.5 kg/m2 and those with a BMI ≥ 25 kg/m2 had a high risk of fatal illness. Maintaining a healthy weight is important not only to prevent chronic cardiometabolic diseases, but also to improve the outcome of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.